When a stock is rated as a “strong buy,” it typically means that analysts believe the stock has significant potential for growth and that the current price is undervalued. Analysts use a variety of methods to evaluate stocks, including financial analysis, market trends, and company performance. A “strong buy” rating is typically the highest rating an analyst will give to a stock.
Here are three “Strong Buy” stocks from Wall Street –
EVgo, Inc. – SYM: EVGO
Recent Price: $4.98
Price Target: $9.75
Firms with Buy Rating: Stifel Nicolaus, Credit Suisse, Cantor Fitzgerald
Description: EVgo, Inc. owns and operates a direct current fast charging network for electric vehicles (EVs) in the United States. The company offers electricity directly to drivers, who access its publicly available networked chargers.
===
PlayAGS, Inc. – SYM: AGS
Recent Price: $5.75
Price Target: $10.67
Firms with Buy Rating: Jefferies, Truist Financial, Stifel Nicolaus
Description: PlayAGS, Inc. designs and supplies gaming products and services for the gaming industry in the United States and internationally. It operates through three segments: Electronic Gaming Machines (EGM), Table Products, and Interactive Games (Interactive). The EGM segment offers various video slot titles for the marketplace; and EGM cabinets, including the Orion Starwall, Orion Curve Premium, Big Red, Orion Portrait, Orion Slant, Orion Curve, Orion Upright, and ICON. This segment also provides conversion kits that allow existing game titles to be converted to other game titles offered within that operating platform. It serves Class II Native American and Mexico, as well as Class III Native American, commercial, and charitable jurisdictions. The Table Products segment offers table products, including live felt table games, side bet offerings, progressives, card shufflers, signage, and other ancillary table game equipment, as well as table technology related to blackjack, poker, baccarat, craps, and roulette. This segment also provides Dex S, a single deck card shuffler for poker tables. Its brands include In Bet Gaming, Buster Blackjack, Double Draw Poker, and Criss Cross Poker. The Interactive segment offers a platform for business-to-business content aggregation used by real-money gaming and sports-betting partners; and business-to-consumer social casino games through its mobile app, Lucky Play Casino. The company was formerly known as AP Gaming Holdco, Inc. and changed its name to PlayAGS, Inc. in December 2017. PlayAGS, Inc. was incorporated in 2005 and is headquartered in Las Vegas, Nevada.
===
GE HealthCare Technologies Inc. – SYM: GEHC
Recent Price: $77.36
Price Target: $91.25
Firms with Buy Rating: Piper Sandler, Evercore ISI, Mizuho Securities
Description: GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women’s health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women’s health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
